Abstract
Free full text
Central serous chorioretinopathy following oral tadalafil
Sir,
We report a case of central serous chorioretinopathy (CSCR) following oral tadalafil (Cialis, Lilly-ICOS LLC) use. A review of the literature found one post-marketing surveillance study in which patients with CSCR showed no increase in prescription exposure to phosphodiesterase type 5 (PDE-5) enzyme inhibitors compared with their age-matched controls.1
Case report
A 51-year-old man with no significant past medical history presented with painless reduced central vision in the left eye of 2 weeks duration. His vision became blurred within 24h of taking tadalafil for enhanced erectile function. He was on no other medication. Examination revealed visual acuities of 3/24 left and 6/5 right, and a large left serous macular detachment. The patient was asked to discontinue tadalafil. Five days later, his left visual acuity improved to 6/12 and the subretinal fluid reduced (Figure 1).
Comment
Our patient had a rapid and dramatic response after commencing and discontinuing tadalafil. This case could be an event of association, but could also be cause and effect, as explained below.
PDE-5 inhibitors modify retinal and choroidal blood flow by their pharmacological effects on the PDE-5 enzyme, which is expressed on retinal and choroidal vasculature. This mechanism involving slowing of choroidal blood flow is also seen in the pathogenesis of CSCR.2 The resultant increased hydrostatic pressure within the choroid affects the ability of the overlying RPE to pump fluid from the retina to the choroid.3
A recent randomised controlled trial showed that when tadalafil was used in therapeutic doses daily for 6 months, there was no adverse significant effect on visual function or ocular anatomy.4 Tadalafil may be used once daily or as needed in doses of 2.5–20mg. Our patient admitted to taking repeated doses larger than 20mg to achieve a more desired erectile effect.
This case report highlights that patients should be advised not to exceed the maximum dose of tadalafil. This case also reminds us that patients with CSCR need to be asked a thorough drug history (including recreational drugs); this is perhaps overlooked in this group, who are usually healthy and young.
Notes
The authors declare no conflict of interest.
References
- French DD, Margo CE. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina. 2010;30 (2:271–274. [Abstract] [Google Scholar]
- Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121:26–34. [Abstract] [Google Scholar]
- Klais C, Ober M, Ciardella A, Yannuzzi L.Central serous chorioretinopathyIn: Ryan S (ed). Retina4th edn, Vol 2,Elsevier/Mosby: Philadelphia; 20061135–1139. [Google Scholar]
- Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber RG, Coupland SG, et al. ERG Testing During Chronic PDE5 Inhibitor Administration (ERG-PDE5i) Consortium Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol. 2009;127 (4:367–373. [Abstract] [Google Scholar]
Articles from Eye are provided here courtesy of Nature Publishing Group
Full text links
Read article at publisher's site: https://doi.org/10.1038/eye.2011.250
Read article for free, from open access legal sources, via Unpaywall: https://www.nature.com/articles/eye2011250.pdf
Citations & impact
Impact metrics
Article citations
Case - Central serous retinopathy following topical intraurethral corticosteroid use for urethral stricture secondary to lichen sclerosus.
Can Urol Assoc J, 18(1):E40-E42, 01 Jan 2024
Cited by: 0 articles | PMID: 37812789 | PMCID: PMC10766331
Chronic Central Serous Chorioretinopathy with Pigment Epithelium Detachment Treated with Sildenafil: A Case Report.
Case Rep Ophthalmol, 13(3):692-699, 19 Sep 2022
Cited by: 0 articles | PMID: 36845460 | PMCID: PMC9944586
Pathophysiology of central serous chorioretinopathy: a literature review with quality assessment.
Eye (Lond), 36(5):941-962, 15 Oct 2021
Cited by: 14 articles | PMID: 34654892 | PMCID: PMC9046392
Review Free full text in Europe PMC
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
J Ophthalmic Vis Res, 16(2):248-259, 29 Apr 2021
Cited by: 6 articles | PMID: 34055262 | PMCID: PMC8126729
Review Free full text in Europe PMC
Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review.
Int J Retina Vitreous, 6:38, 06 Aug 2020
Cited by: 9 articles | PMID: 32782824 | PMCID: PMC7412824
Review Free full text in Europe PMC
Go to all (11) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Central serous chorioretinopathy following oral tadalafil intake.
Clin Exp Optom, 97(5):473-474, 25 Feb 2014
Cited by: 5 articles | PMID: 24612146
Central serous chorioretinopathy due to tadalafil use.
Int Ophthalmol, 33(2):177-180, 14 Oct 2012
Cited by: 4 articles | PMID: 23065016
[Serous central chorioretinopathy and tadalafil: a case report].
J Fr Ophtalmol, 35(2):121.e1-5, 15 Jun 2011
Cited by: 2 articles | PMID: 21680058
Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Expert Opin Pharmacother, 13(10):1481-1494, 01 Jul 2012
Cited by: 13 articles | PMID: 22725705
Review